We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
28 own
10 watching
Current Price
$7.02
$-0.45
(-6.02%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
1,313.59M
52-Week High
50.09
52-Week Low
6.9
Average Volume
0.55M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,313.59M
52-Week High50.09
52-Week Low6.9
Average Volume0.55M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
We are a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. Our vision is to revolutionize medicine and open new avenues for developing therapies by enabling the body to make its own drugs. --- Our principal executive offices are located at Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany. Our telephone number at this address is +49 7071 98830. Our principal website is www.curevac.com.
Read More
News & Events about Stockal+Disclaimer.pdf.
Accesswire
18days ago
Data confirm CV8102's safety and ability to strongly mobilize the immune system against tumorsFinal data of complete Phase 1 dose-escalation and expansion study expected in H1 2023TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 11, 2022 / CureVac N.V. (Nasdaq:CVAC), a global...
Accesswire
6 months ago
CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backboneThe partnership combines CureVac's mRNA technology with myNEO's platform for the discovery and selection of tumor antigens predicted to elicit strong immune responsesTogether with...
Accesswire
6 months ago
Progressing broad vaccine development program in collaboration with GSK, with second-generation candidates in Phase 1 clinical trials for COVID-19 and influenzaCureVac eligible to a €10 million milestone payment from GSK for the initiation of the influenza clinical trialIncreasing momentum...
Accesswire
7 months ago
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 22, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates...
Ticker Report
7 months ago
CureVac (NASDAQ:CVAC Get Rating)s share price gapped up before the market opened on Tuesday . The stock had previously closed at $16.01, but opened at $16.59. CureVac shares last traded at $16.24, with a volume of 1,376 shares changing hands. A number of brokerages have commented on ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$7.02
$-0.45
(-6.02%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00